Functional Interactive Effects of D1 and D2 Dopamine Receptor Blockade

  • A. I. Salama
  • C. F. Saller
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 204)


Multiple types of dopamine (DA) receptors have been shown to exist in the striatum (Seeman, 1980). These receptor populations have been divided into those which stimulate the enzyme adenylate cyclase (D2 sites) and those which are not directly linked to or suppress this enzyme (D2 sites, Kebabian and Calne, 1978; Stoof and Kebabian, 1984). Until now, the functional effects of DA receptor activation in the brain have been attributed to drug action at D2 receptor sites. Thus, good correlations exist between the ability of neuroleptic drugs to displace 3H-spiroperidol from specific binding sites on D2 receptors (Seeman, 1980) and their antipsychotic activity (Seeman, 1977; Creese et al., 1979; Seeman, 1980). Although no obvious physiological function for D1 sites in brain is known, recent evidence has suggested an interaction between D1 and D2 sites. For example, SKF 38393, a D1 agonist, stimulates the efflux of cAMP from superfused striatal tissue slices, and this stimulation is antagonized by LY 141865, a selective D2 agonist.


Adenylate Cyclase Receptor Blockade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Boyce, S., Kelly, E., Davis, A., Fleminger, S., Jenner, P., and Mardsden, C. D., 1985, SCH 23390 may alter dopamine-mediated motor behavior via striatal D-1 receptors, Biochem. Pharmacol., 34:1665.PubMedCrossRefGoogle Scholar
  2. Creese, I., Burt, D. R., and Snyder, S. H., 1979, Biochemical actions of neuroleptic drugs: Focus on the dopamine receptor, in: “Handbook of Psychopharmacology,” L. L. Iversen, S. D. Iversen, and S. H. Snyder, eds., Plenum Press, New York.Google Scholar
  3. Enjalbert, A., and Bockaert, J., 1983, Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary, Mol. Pharmacol., 23:576.PubMedGoogle Scholar
  4. Hicks, P. E., Shoemaker, H., and Langer, S. Z., 1984, 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain, Eur. J. Pharmacol., 105:339.PubMedCrossRefGoogle Scholar
  5. Hyttel, J., 1983, SCH 23390 — The first selective D1 antagonist, Eur. J. Pharmacol., 91:153.Google Scholar
  6. Hyttel, J., 1984, Functional evidence for selective dopamine D1 receptor blockade by SCH 23390, Neuropharmacol., 23:1395.CrossRefGoogle Scholar
  7. Iorio, L. C., Barnett, A., Leitz, F. H., Hower, V. P., and Korduba, C. A., 1983, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J. Pharmacol. Exp. Ther., 226:462.PubMedGoogle Scholar
  8. Kebabian, J. W., and Calne, D. B., 1978, Multiple receptors for dopamine, Nature, 277:93.CrossRefGoogle Scholar
  9. Lehman, J., and Langer, S. Z., 1983, The striatal cholinergic interneurons: Synaptic target of dopaminergic terminals? Neurosci., 10:1105.CrossRefGoogle Scholar
  10. Mailman, R. B., Schulz, D. W., Lewis, M. H., Staples, L., Rolloma, H., and Dehaven, D. L., 1984, SCH 23390: A selective D1 antagonist with potent D2 behavioral actions, Eur. J. Pharmacol., 101:159.PubMedCrossRefGoogle Scholar
  11. Meller, E., Kuga, S., Friedhoff, A., and Goldstein, M., 1985, Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist, Life Sci., 36:1857.PubMedCrossRefGoogle Scholar
  12. Mereu, G., Collu, M., Ongini, E., Biggio, G., and Gessa, G. L., 1985, SCH 23390, a selective dopamine D1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine, Eur. J. Pharmacol., 111:393.PubMedCrossRefGoogle Scholar
  13. Onali, P., Olianas, M. C., and Gessa, G. L., 1984, Selective blockade of dopamine D1 receptors by SCH 23390 discloses striatal dopamine D2 receptors mediating the inhibition of adenylate cyclase in rats, Eur. J. Pharmacol., 99:127.PubMedCrossRefGoogle Scholar
  14. Plantje, J. F., Daus, F. J., Hansen, H. A., and Stoof, J. C., 1984, SCH 23390 blocks D1 and D2 dopamine receptors in rat neostriatum in vitro, Nauyn-Schmiedeberg’s Arch Pharmacol., 327:180.CrossRefGoogle Scholar
  15. Rosengarten, H., Schweiter, J. W., and Friedhoff, A. J., 1983, Induction of oral dyskinesias in naive rats by D1 stimulation, Life Sci., 33:2479.PubMedCrossRefGoogle Scholar
  16. Saller, C. F., and Salama, A. I., 1985, Dopamine receptor subtypes: In vivo biochemical evidence for functional interaction, Eur. J. Pharmacol., 109:297.PubMedCrossRefGoogle Scholar
  17. Sailer, C. F., and Salama, A. I., 1986a, D1 and D2 dopamine receptor blockade: Interactive effects in vitro and in vivo, J. Pharmacol. Exptl. Therap., 236:714.Google Scholar
  18. Sailer, C. F., and Salama, A. I., 1986b, D1 dopamine receptor stimulation elevates plasma prolactin levels, Eur. J. Pharmacol., 122:139.CrossRefGoogle Scholar
  19. Scatton, B., 1982, Further evidence for the involvement of D2, but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission, Life Sci., 31:2883.PubMedCrossRefGoogle Scholar
  20. Seeman, P., 1977, Anti-schizophrenic drugs: Membrane receptor sites of action, Biochem. Pharmacol., 26:1741.PubMedCrossRefGoogle Scholar
  21. Seeman, P., 1980, Brain dopamine receptors, Pharmacological Reviews, 32:230.Google Scholar
  22. Setler, P. E., Sarau, H. M., Zirkle, C. L., and Saunders, H. L., 1978, The central effects of a novel dopamine agonist, Eur. J. Pharmacol., 50:419.PubMedCrossRefGoogle Scholar
  23. Starke, K., Spach, L., Lang, J. D., and Adelung, C., 1983, Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus, Nauyn-Schmiedeberg’s Arch Pharmacol., 323:298.CrossRefGoogle Scholar
  24. Stoof, J. C., and Kebabian, J. W., 1981, Opposing roles for D1 and D2 dopamine receptors in efflux of cAMP from rat neostriatum, Nature, 294:366.PubMedCrossRefGoogle Scholar
  25. Stoof, J. C., and Kebabian, J. W., 1982, Independent in vitro regulation by D2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum, Brain Res., 250:263.PubMedCrossRefGoogle Scholar
  26. Stoof, J. C., and Kebabian, J. W., 1984, Two dopamine receptors: Biochemistry, physiology and pharmacology, Life Sci., 35:2281.PubMedCrossRefGoogle Scholar
  27. Swennen, L., and Denef, C., 1982, Physiological concentrations of dopamine decrease adenosine 3’ 5’ monophosphate levels in cultured rat anterior pituitary cells and enriched populations of lactotrophs: Evidence for casual relationship to inhibition of prolactin release, Endocrinology, 111:398.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • A. I. Salama
    • 1
  • C. F. Saller
    • 1
  1. 1.Department of Pharmacology, Stuart PharmaceuticalsDiv. of ICI Americas Inc.WilmingtonUSA

Personalised recommendations